GRAIL reported a 43% year-over-year increase in revenue to $32.0 million for the second quarter of 2024. The company's strategic update includes reducing overall spend and focusing on core multi-cancer early detection priorities, which is expected to extend the cash runway into 2028.
Revenue in the second quarter was $32.0 million, representing 43% growth year over year.
Net loss for the quarter was $(1.6) billion, including amortization and impairment of acquisition-related intangible items.
Adjusted gross profit was $16.0 million.
Cash and cash equivalents totaled $958.8 million as of June 30, 2024.
GRAIL anticipates reducing its burn in 2025 to $325 million and expects $27 million in savings in 2024, net of anticipated severance and benefits costs.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance